Functional imaging in head and neck cancer

Current Oncology Reports

Volumn 7, Issue 2, 2005, Pages 137-144

  Kutler, David I ^a   Wong, Richard J ^a   Kraus, Dennis H ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; FLUORODEOXYGLUCOSE F 18;

CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; HEAD AND NECK CANCER; HUMAN; IMAGING SYSTEM; INTERMETHOD COMPARISON; METASTASIS; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; REVIEW; SENSITIVITY AND SPECIFICITY; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE;

EID: 16844378319     PISSN: 15233790     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11912-005-0040-y     Document Type: Review

References (55)

1. Parkin DM, Pisani P, Ferlay J: Global cancer statistics. CA Cancer J Clin 1999, 49:33-64, 1.
2. Greenlee RT, Hill-Harmon MB, Murray T, Thun M: Cancer statistics, 2001. CA Cancer J Clin 2001, 51:15-36.
3. Lindberg R: Distribution of cervical lymph node metastases from squamous cell carcinoma of the upper respiratory and digestive tracts. Cancer 1972, 29:1446-1449.
4. Kau RJ, Alexiou C, Laubenbacher C: Lymph node detection of head and neck squamous cell carcinomas by positron emission tomography with fluorodeoxyglucose F 18 in a routine clinical setting. Arch Otolaryngol Head Neck Surgery 1999, 125:1322-1328.
5. Adams S, Baum RP, Stuckensen T, et al.: Prospective comparison of 18F-FDG PET with conventional imaging modalities (CT, MRI, US) in lymph node staging of head and neck cancer. Eur J Nucl Med 1998, 25:1255-1260.
6. Greven KM, Williams DW III, McGuirt WF Sr, et al.: Serial positron emission tomography scans following radiation therapy of patients with head and neck cancer. Head Neck 2001, 23: 42-946.
7. Paulus P, Sambon A, Vivegnis D, et al.: 18FDG-PET for the assessment of primary head and neck tumors: clinical, computed tomography, and histopathological correlation in 38 patients. Laryngoscope 1998, 108:1578-1583.
8. Hannah SC, Scott AM, Tochon-Danguy H: Evaluation of 18F-fluorodeoxyglucose positron emission tomography and computed tomography with histopathologic correlation in the initial staging of head and neck cancer. Ann Surg 2002, 236:208-217.
9. O'Brien CJ, Smith JW, Soong SJ, et al.: Neck dissection with and without radiotherapy: prognostic factors, patterns of recurrence, and survival. Am J Surg 1986, 152:456-463.
10. Johnson JT, Myers EN, Bedetti CD, et al.: Cervical lymph node metastases: incidence and implications of extracapsular carcinoma. Arch Otolaryngol 1985, 111:534-537.
11. Jones AS, Roland NJ, Field JK, Phillips DE: The level of cervical lymph node metastases: their prognostic relevance and relationship with head and neck squamous carcinoma primary sites. Clin Otolaryngol 1994, 19:63-69.
12. Teichgraeber JF, Clairmont AA: The incidence of occult metastases for cancer of the oral tongue and floor of the mouth: treatment rationale. Head Neck Surg 1984, 7:15-21.
13. van den Brekel MW, Stel HV, Castelijns JA, et al.: Cervical lymph node metastasis: assessment of radiologic criteria. Radiology 1990, 177:379-384.
14. Civantos FJ, Gomez C, Duque C, et al.: Sentinel node biopsy in oral cavity cancer: correlation with PET scan and immunohistochemistry. Head Neck 2003, 25:1-9.
15. Hyde NC, Prvulovich E, Newman L, et al.: A new approach to pre-treatment assessment of the N0 neck in oral squamous cell carcinoma: the role of sentinel node biopsy and positron emission tomography. Oral Oncol 2003, 39:350-360.
16. McGuirt WF, Williams DW, III, Keyes JW Jr, et al.: A comparative diagnostic study of head and neck nodal metastases using positron emission tomography. Laryngoscope 1995, 105: 73-375.
17. Stoeckli SJ, Steinert H, Pfaltz M, Schmid S: Is there a role for positron emission tomography with 18F-fluorodeoxyglucose in the initial staging of nodal negative oral and oropharyngeal squamous cell carcinoma? Head Neck 2002, 24:345-349.
18. Schwartz LH, Ozsahin M, Zhang GN, et al.: Synchronous and metachronous head and neck carcinomas. Cancer 1994, 74:1933-1938.
19. Johansen J, Eigtved A, Buchwald C, et al.: Implication of 18F-fluoro-2-deoxy-D-glucose positron emission tomography on management of carcinoma of unknown primary in the head and neck: a Danish cohort study. Laryngoscope 2002, 112:2009-2014.
20. Stokkel MP, Terhaard CH, Hordijk GJ, van Rijk PP: The detection of local recurrent head and neck cancer with fluorine-18 fluorodeoxyglucose dual-head positron emission tomography. Eur J Nucl Med 1999, 26:767-773.
21. Schwartz DL, Rajendran J, Yueh B, et al.: Staging of head and neck squamous cell cancer with extended-field FDG-PET. Arch Otolaryngol Head Neck Surg 2003, 129:1173-1178.
22. Wax MK, Myers LL, Gabalski EC, et al.: Positron emission tomography in the evaluation of synchronous lung lesions in patients with untreated head and neck cancer. Arch Otolaryngol Head Neck Surg 2002, 128:703-707.
23. Keyes JW, Chen MY, Watson NE, et al.: FDG-PET evaluation of head and neck cancer: value of imaging the thorax. Head Neck 2000, 22:105-110.
24. Goerres GW, Schmid DT, et al.: Impact of whole body positron emission tomography on initial staging and therapy in patients with squamous cell carcinoma of the oral cavity. Oral Oncol 2003, 39:547-551.
25. Schmid DT, Stoeckli SJ, Bandhauer F, et al.: Impact of positron emission tomography on the initial staging and therapy in locoregional advanced squamous cell carcinoma of the head and neck. Laryngoscope 2003, 113:888-891.
26. Teknos TN, Rosenthal EL, Lee D, et al.: Positron emission tomography in the evaluation of stage III and IV head and neck cancer. Head Neck 2001, 23:1056-1060.
27. Shah JP: Patterns of cervical lymph node metastasis from squamous carcinomas of the upper aerodigestive tract. Am J Surg 1990, 160:405-409.
28. Davidson BJ, Kulkarny V, Delacure MD, Shah JP: Posterior triangle metastases of squamous cell carcinoma of the upper aerodigestive tract. Am J Surg 1993, 166:395-398.
29. Kole AC, Nieweg OE, Pruim J, et al.: Detection of unknown occult primary tumors using positron emission tomography. Cancer 1998, 82:1160-1166.
30. Aassar OS, Fischbein NJ, Caputo GF, et al.: Metastatic head and neck cancer: role and usefulness of FDG PET in locating occult primary tumors. Radiology 1999, 210: 77-181.
31. Mendenhall WM, Mancuso AA, Parsons JT, et al.: Diagnostic evaluation of squamous cell carcinoma metastatic to cervical lymph nodes from an unknown head and neck primary site. Head Neck 1998, 20:739-744.
32. Greven KM, Keyes JW Jr, Williams DW III, et al.: Occult primary tumors of the head and neck: lack of benefit from positron emission tomography imaging with 2-[F-18]fluoro-2-deoxy-D-glucose. Cancer 1999, 86:114-118.
33. Fogarty GB, Peters LJ, Stewart J, et al.: The usefulness of fluorine 18-labelled deoxyglucose positron emission tomography in the investigation of patients with cervical lymphadenopathy from an unknown primary tumor. Head Neck 2003, 25:138-145.
34. Goerres GW, Schmid DT, Bandhauer F, et al.: Positron emission tomography in the early follow-up of advanced head and neck cancer. Arch Otolaryngol Head Neck Surg 2004, 130:105-109.
35. Lonneux M, Lawson G, Ide C, et al.: Positron emission tomography with fluorodeoxyglucose for suspected head and neck tumor recurrence in the symptomatic patient. Laryngoscope 2000, 110:1493-1497.
36. Lowe VJ, Boyd JH, Dunphy FR, et al.: Surveillance for recurrent head and neck cancer using positron emission tomography. J Clin Oncol 2000, 18:651-658.
37. Wong RJ, Lin DT, Schoder H, et al.: Diagnostic and prognostic value of [(18)F]fluorodeoxyglucose positron emission tomography for recurrent head and neck squamous cell carcinoma. J Clin Oncol 2002, 20:4199-4208.
38. Greven KM, Williams DW III, Keyes JW Jr, et al.: Distinguishing tumor recurrence from irradiation sequelae with positron emission tomography in patients treated for larynx cancer. Int J Radiat Oncol Biol Phys 1994, 29:841-845.
39. Terhaard CH, Bongers V, van Rijk PP, Hordijk GJ: F-18-fluorodeoxy-glucose positron-emission tomography scanning in detection of local recurrence after radiotherapy for laryngeal/pharyngeal cancer. Head Neck 2001, 23:933-941.
40. Halfpenny W, Hain SF, Biassoni L, et al.: FDG-PET: a possible prognostic factor in head and neck cancer. Br J Cancer 2002, 86:512-516.
41. Allal AS, Dulguerov P, Allaoua M, et al.: Standardized uptake value of 2-[(18)F] fluoro-2-deoxy-D-glucose in predicting outcome in head and neck carcinomas treated by radiotherapy with or without chemotherapy. J Clin Oncol 2002, 20: 398-1404.
42. Rege S, Safa AA, Chaiken L, et al.: Positron emission tomography: an independent indicator of radiocurability in head and neck carcinomas. Am J Clin Oncol 2000, 23:164-169.
43. Brun E, Kjellen E, Tennvall J, et al.: FDG PET studies during treatment: prediction of therapy outcome in head and neck squamous cell carcinoma. Head Neck 2002, 24:127-135.
44. Lapela M, Eigtved A, Jyrkkio S, et al.: Experience in qualitative and quantitative FDG PET in follow-up of patients with suspected recurrence from head and neck cancer. Eur J Cancer 2000, 36:858-867.
45. Bar-Shalom R, Yefremov N, Guralnik L, et al.: Clinical performance of PET/CT in evaluation of cancer: additional value for diagnostic imaging and patient management. J Nucl Med 2003, 44:1200-1209.
46. Cohade C, Osman M, Leal J, Wahl RL: Direct comparison of (18)F-FDG PET and PET/CT in patients with colorectal carcinoma. J Nucl Med 2003, 44:1797-1803.
47. Schoder H, Yeung HW, Gonen M, et al.: Head and neck cancer: clinical usefulness and accuracy of PET/CT image fusion. Radiology 2004, 231:65-72.
48. Koh WJ, Rasey JS, Evans ML, et al.: Imaging of hypoxia in human tumors with [F-18]fluoromisonidazole. Int J Radiat Oncol Biol Phys 1992, 22:199-212.
49. Chao KS, Bosch WR, Mutic S, et al.: A novel approach to overcome hypoxic tumor resistance: Cu-ATSM-guided intensity-modulated radiation therapy. Int J Radiat Oncol Biol Phys 2001, 49: 171-1182.
50. Jungehulsing M, Scheidhauer K, Damm M, et al.: 2[F]-fluoro-2-deoxy-D-glucose positron emission tomography is a sensitive tool for the detection of occult primary cancer (carcinoma of unknown primary syndrome) with head and neck lymph node manifestation. Otolaryngol Head Neck Surg 2000, 123:294-301.
51. Bohuslavizki KH, Klutmann S, Kroger S, et al.: FDG PET detection of unknown primary tumors. J Nucl Med 2000, 41: 16-822.
52. Hanasono MM, Kunda LD, Segall GM, et al.: Uses and limitations of FDG positron emission tomography in patients with head and neck cancer. Laryngoscope 1999, 109:880-885.
53. Safa AA, Tran LM, Rege S, et al.: The role of positron emission tomography in occult primary head and neck cancers. Cancer J Sci Am 1999, 5:214-218.
54. Farber LA, Benard F, Machtay M, et al.: Detection of recurrent head and neck squamous cell carcinomas after radiation therapy with 2-18F-fluoro-2-deoxy-D-glucose positron emission tomography. Laryngoscope 1999, 109:970-975.
55. Li P, Zhuang H, Mozley PD, et al.: Evaluation of recurrent squamous cell carcinoma of the head and neck with FDG positron emission tomography. Clin Nucl Med 2001, 26:131-135.